The Chalcogen Is Bonded Directly To Two Carbon Atoms Patents (Class 514/239.2)
-
Patent number: 7297794Abstract: Phenoxy amine compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.Type: GrantFiled: November 13, 2002Date of Patent: November 20, 2007Assignee: Emisphere Technologies, Inc.Inventors: David Gschneidner, Kelly Kraft, Chen Zhu, Yi Chen
-
Patent number: 7294623Abstract: A compound of formula (I) (I) wherein R is H; Ar is an aromatic group selected from phenyl; X is a phenyl group; R? is H or C1-C4 alkyl; each R1 is independently H or C1-C4 alkyl; and pharmaceutically acceptable salts thereofType: GrantFiled: August 18, 2003Date of Patent: November 13, 2007Assignee: Eli Lilly and CompanyInventors: Barry Peter Clark, Peter Thaddeus Gallagher, Helen Louise Haughton
-
Patent number: 7276503Abstract: Disclosed herein are methods of treating an individual suffering from, chronic fatigue syndrome. The methods generally include administration of a therapeutic amount of optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, to the individual. Embodiments of these methods can diminish adverse side effects.Type: GrantFiled: February 7, 2006Date of Patent: October 2, 2007Assignee: Pharmacia & Upjohn CompanyInventors: Erik H. F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor
-
Patent number: 7241762Abstract: Disclosed herein are methods of treating an individual suffering from peripheral neuropathy. The methods generally include administration of a therapeutic amount of racemic reboxetine, or a pharmaceutically acceptable salt thereof, to the individual.Type: GrantFiled: February 7, 2006Date of Patent: July 10, 2007Assignee: Pharmacia & Upjohn CompanyInventors: Erik H. F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor
-
Patent number: 7141560Abstract: The present invention relates to alanine 2,6-dialkoxyphenyl ester derivatives having the general formula I The invention also relates to pharmaceutical compositions comprising said derivatives, and to the use of these alanine 2,6-dialkoxyphenyl ester derivatives as hypnotics for the induction and maintenance of general anaesthesia.Type: GrantFiled: January 17, 2002Date of Patent: November 28, 2006Assignee: Akzo Nobel N.V.Inventors: Niall Morton Hamilton, David Jonathan Bennett
-
Patent number: 6987107Abstract: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.Type: GrantFiled: January 23, 2002Date of Patent: January 17, 2006Assignee: Pharmacia & Upjohn CompanyInventors: Erik H. F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor, Lars Birgerson
-
Patent number: 6972292Abstract: The present invention relates to certain substituted polyketides of formula I, wherein A, B, C, D, E, F and m are as defined herein, pharmaceutical compositions containing said compounds, and the use of said compounds in treating tumors.Type: GrantFiled: August 5, 2002Date of Patent: December 6, 2005Assignee: Novartis AGInventors: Frederick Ray Kinder, Jr., Kenneth W. Bair, Timothy M. Ramsey, Michael L. Sabio
-
Patent number: 6964963Abstract: The present invention describes a process for preparing 4-amino-1-naphthol ethers which is characterized in that naphthol ethers are first prepared from 1-naphthols, the former are then converted to the corresponding 4-acetamino-1-naphthol ethers and then the acyl group is cleaved off, and further describes 4-acetamino-1-naphthol ethers obtained thereby.Type: GrantFiled: August 27, 2002Date of Patent: November 15, 2005Assignee: Bayer AktiengesellschaftInventors: Joachim Komoschinski, Herbert Diehl
-
Patent number: 6964962Abstract: A composition comprising: (a) a pharmaceutically effective amount of reboxetine; and selected from the group consisting of clozapine, olanzapine, risperidone and mixtures thereof (b) a pharmaceutically effective amount of one or more neuroleptic agents or a pharmaceutically effective salt thereof is provided.Type: GrantFiled: December 28, 2001Date of Patent: November 15, 2005Assignee: Pharmacia & Upjohn CompanyInventors: Erik Ho Fong Wong, Christopher C. Gallen, Torgny Svensson
-
Patent number: 6900203Abstract: (R)-6F-phenylephrine, essentially free of (S)-6F-phenylephrine, and an anesthetic formulation comprising (R)-6F-epinephrin or (R)-6F-phenylephrine and having improved stability compared to formulations containing their non-fluorinated analog, are disclosed. Further disclosed is a method of providing vasoconstriction in a mammal by administering the anesthetic formulation. The anesthetic composition can include an anesthetic, an (R)-chiral compound having the structure: wherein R1, R2, and R4 are independently selected from —H or —F, at least one of R1, R2, and R4 is —F, and R3 is selected from —OH, —H or —F, or a pharmaceutically acceptable salt or ester thereof, said vasoconstrictor being essentially free of the (S)-chiral form. Also, a method of chiral addition of cyanide to a ring-fluorinated phenaldehyde, employing an almond hydroxynitrile lyase enzyme, provided in the form of a reversibly soluble polymer conjugate ((R)-Finezyme™-H series biocatalysts) is disclosed.Type: GrantFiled: July 8, 2002Date of Patent: May 31, 2005Assignee: Polium Technologies, Inc.Inventors: Hamilton J. Lenox, Elena Terentieva, Mikhail Y. Gololobov
-
Patent number: 6900243Abstract: There are provided novel compounds of formula (I), wherein R1, R2, X, Y, V, W and Z are as defined in the specification, and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease and pain.Type: GrantFiled: February 20, 2001Date of Patent: May 31, 2005Assignee: AstraZeneca ABInventors: David Cheshire, Stephen Connolly, David Cox, Antonio Mete
-
Patent number: 6878706Abstract: Compounds according to the following formula (I): wherein the variables Q and R1 to R6 are as described herein, which reversibly inhibit the cysteine proteases, such as cathepsins K, S, F, L and B; pharmaceutical compositions containing such compounds, and method of treating diseases and pathological conditions exacerbated by these cysteine proteases such as, but not limited to rheumatoid arthritis, multiple sclerosis and other autoimmune diseases, osteoporosis, asthma, Alzheimer's disease, atherosclerosis and endometriosis.Type: GrantFiled: March 27, 2003Date of Patent: April 12, 2005Assignee: Boehringer Ingelheim Pharmaceuticals Inc.Inventors: Thomas A. Gilmore, Eugene Richard Hickey, Weimin Liu, Peter Allen Nemoto, Denice M. Spero
-
Patent number: 6787543Abstract: A compound of the formula (I): in which Z, R1, R2, R8, R10, R11, R12, R13 and R14 are each as defined in the description, or a salt thereof. The object compound of the present invention has pharmacological activities such as Tachykinin antagonism, and is useful for manufacture of a medicament for treating or preventing Tachykinin-mediated diseases.Type: GrantFiled: December 20, 2002Date of Patent: September 7, 2004Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Kazuhiko Take, Chiyoshi Kasahara, Shinji Shigenaga, Hidenori Azami, Yoshiteru Eikyu, Kazuo Nakai, Masataka Morita
-
Publication number: 20040122000Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.Type: ApplicationFiled: October 21, 2003Publication date: June 24, 2004Applicant: Vertex Pharmaceuticals Incorporated.Inventors: Michael R. Hale, Roger Tung, Stephen Price, Robin David Wilkes, Wayne Carl Schairer, Ashley Nicholas Jarvis, Andrew Spaltenstein, Eric Steven Furfine, Vicente Samano, Istvan Kaldor, John Franklin Miller, Michael Stephen Brieger, Ronald George Sherrill
-
Patent number: 6703389Abstract: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.Type: GrantFiled: December 14, 2001Date of Patent: March 9, 2004Assignee: Pharmacia & Upjohn CompanyInventors: Erik H. F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor, Lars Birgerson, Pasquale Cetera
-
Publication number: 20030232829Abstract: This patent application describes the treatment of Addictive disorders, Psychoactive Substance Use disorders, Intoxication disorders, Inhalation disorders, Alcohol addiction, Tobacco addiction and or Nicotine addiction; and Attention Deficit Hyperactivity Disorder (ADHD); comprising administering a therapeutically effective, nontoxic dose of Reboxetine and derivatives and or pharmaceutically acceptable salts thereof to a patient.Type: ApplicationFiled: April 28, 2003Publication date: December 18, 2003Inventors: Fred Hassan, John Michael McCall, Duncan Paul Taylor, Philip F. Von Voigtlander, Erik Ho Fong Wong
-
Patent number: 6642235Abstract: Methods for treating humans suffering from, migraine headaches by inhibiting reuptake of norepinephrine are disclosed. The methods comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine.Type: GrantFiled: January 4, 2002Date of Patent: November 4, 2003Assignee: Pharmacia & Upjohn CompanyInventors: Erik H. F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor
-
Patent number: 6610690Abstract: This application relates to methods for treating humans suffering from, fibromyalgia or other somatoform disorders where inhibiting reuptake of norepinephrine is a benefit. The methods comprise a compound having a pharmacological selectivity of serotonin (K1)/norepinephrine (K1) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine.Type: GrantFiled: January 4, 2002Date of Patent: August 26, 2003Assignee: Pharmacia & Upjohn CompanyInventors: Erik H. F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor
-
Patent number: 6602869Abstract: This invention relates to novel compounds of formula (I) wherein R1 represents a polymer, aryl or alkyl group, R2 represents a hydrogen atom, a halogen atom, a radical CN, CF3, OH, OCF3, COOH, R7, OR7 or OCOR7, R3 represents an aryl or alkyl halogen, R4 represents an alkyl radical. The invention also relates to a cosmetic composition comprising said compounds and to the use thereof to reduce and/or curb hair loss i.e. to increase and/or stimulate the growth of said hair.Type: GrantFiled: November 21, 2001Date of Patent: August 5, 2003Assignee: L'Oreal S.A.Inventors: Jean-Baptiste Galey, Maria Dalko, Lionel Breton
-
Patent number: 6586431Abstract: The present invention relates to compounds of the formula I, wherein Z1, Z2, X, Q, R1, R2 and R3 are defined as in the specification, pharmaceutical compositions containing such compounds the use of such compounds to treat neurological and gastrointestinal disorders.Type: GrantFiled: May 31, 2000Date of Patent: July 1, 2003Assignee: Pfizer IncInventors: Spiros Liras, Martin P. Allen, Barbara E. Segelstein
-
Patent number: 6586427Abstract: This patent application describes the treatment of Addictive disorders, Psychoactive Substance Use disorders, Intoxication disorders, Inhalation disorders, Alcohol addiction, Tobacco addiction and or Nicotine addiction; and Attention Deficit Hyperactivity Disorder (ADHD); comprising administering a therapeutically effective, nontoxic dose of Reboxetine and derivatives and or pharmaceutically acceptable salts thereof to a patient.Type: GrantFiled: August 13, 2001Date of Patent: July 1, 2003Assignee: Pharmacia & Upjohn CompanyInventors: Fred Hassan, John Michael McCall, Duncan Paul Taylor, Philip F. Von Voigtlander, Erik Ho Fong Wong
-
Patent number: 6541471Abstract: A compound of formula (I): wherein: G represents a group such as: wherein R1 and R2 independently represent a hydrogen atom or an alkyl, cycloalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl or heteroarylalkyl group, or, R1 and R2 together with the nitrogen atom form a heterocycloalkyl group, R3 represents a hydrogen atom or an alkyl or optionally substituted phenyl group, Ra represents a hydroxy group, a linear or branched (C1-C6)alkoxy group or an amino group, Rb and Rc, which may be identical or different, each represents a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, a hydroxy group or a trihaloalkyl group, m is an integer of from 0 to 1 inclusive, n and q are integers of from 0 to 6 inclusive, p and r are integers of from 1 to 6 inclusive, its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base; and medicinal products containing the same which are useful as a TXA2 receptType: GrantFiled: July 12, 2002Date of Patent: April 1, 2003Assignee: Les Laboratoires ServierInventors: Gilbert Lavielle, Thierry Dubuffet, Bernard Cimetiere, Tony Verbeuren, Serge Simonet, Christine Vayssettes-Courchay
-
Patent number: 6541523Abstract: The present invention relates to methods and compositions comprising a very low dose of cyclobenzaprine or metabolite thereof for preventing and treating sleep disturbances and illnesses manifested with sleep dysfunction including fibromyalgia syndrome, chronic fatigue syndrome, sleep disorders, psychogenic pain disorders or chronic pain syndromes or symptoms thereof. The present invention further relates to methods and compositions for treating sleep disturbances, chronic pain or fatigue in humans suffering from fibromyalgia syndrome, chronic fatigue syndrome, sleep disorders, psychogenic pain disorders, chronic pain syndromes using a very low dose of cyclobenzaprine.Type: GrantFiled: June 27, 2001Date of Patent: April 1, 2003Assignee: Vela Pharmaceuticals, Inc.Inventor: Iredell W. Iglehart, III
-
Publication number: 20030060465Abstract: Compounds of the formula: RC(O)O-spacer-OC(O)R′, wherein (i) RC(O)— is the acyl residue of an NSAID or other pharmaceutically active agent bearing a carboxylic acid function, (ii) spacer is Cn alkyl, (iii) n is from 1 to 6, and (iv) R′ is substituted or unsubstituted heteroaryl or heterocycle, and pharmaceutical compositions thereof.Type: ApplicationFiled: December 18, 2001Publication date: March 27, 2003Inventor: Jamal A. Jilani
-
Patent number: 6511980Abstract: The present invention relates to novel substituted diamine derivatives for the formula wherein R1, R2, R3, R4, X1, X2, X3, X4, A, Y and n are as described in the specification, pharmaceutical compositions containing them and intermediates used in their manufacture. More particularly, the compounds of the invention are motilin receptor antagonists useful for the treatment of associated conditions and disorders such as gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel syndrome.Type: GrantFiled: April 10, 2001Date of Patent: January 28, 2003Assignee: Ortho McNeil Pharmaceutical, Inc.Inventors: Sigmond G. Johnson, Ralph A. Rivero
-
Patent number: 6500826Abstract: The use of panaverium bromide for treating or preventing diseases of the liver and digestive tract caused by excessive cell proliferation therein, is disclosed.Type: GrantFiled: April 26, 1999Date of Patent: December 31, 2002Assignee: Solvay PharmaInventors: Marie-Odile Christen, Joelle Maugard, Huynh Duc, Hans Scherubl, Jan Huizinga, Michael G. Blennerhasset
-
Patent number: 6500827Abstract: This patent application describes a new combination treatment of selective, noradrenaline-reuptake inhibitors (NARI) and specifically, reboxetine, and pindolol to provide rapid relief to patients suffering from depression, general anxiety, attention deficit hyperactivity disorder (ADHD), anxiety disorders such as obsessive compulsive disorders (OCD), panic disorders (PD), social phobia (SD) and the like.Type: GrantFiled: July 11, 2001Date of Patent: December 31, 2002Assignee: Pharmacia & Upjohn CompanyInventor: Duncan Paul Taylor
-
Patent number: 6479491Abstract: The present invention relates to compounds of formula (I), any of it enantiomers, or any mixture thereof, or a pharmaceutically acceptable acid addition salt thereof, wherein R1, R2, R3, R4, R11, R12, R13, R14 and R15 each independently are hydrogen, alkyl, alkoxy, halogen, trifluoromethyl, nitro, cyano, amino, acyl, alkylamino, dialkylamino, aminocarbonyl, or acylamino; R5 is hydrogen, alkyl, alkoxyalkyl, or phenylalkyl; X is —CH2—Z—, Z—CH2—, NH—CO—, —CO—NH—, or —CH═CH—; wherein Z is O, S, CH2, or NH; Y is O, —CH2—W—, —W—CH2—; wherein W is O, or S; and n is 0, 1 or 2. The compounds are useful in the treatment of psychotic disorders.Type: GrantFiled: November 13, 2000Date of Patent: November 12, 2002Assignee: Neurosearch A/SInventors: Oskar Axelsson, Dan Peters, Jorgen Scheel-Kruger, Elsebet Ostergaard Nielsen
-
Publication number: 20020161007Abstract: Estrogen receptor modulators, compositions comprising the compounds and methods relating to the use thereof are described. The compounds may be used in inhibiting the proliferation of and/or induces apoptosis in human breast cancer cells.Type: ApplicationFiled: February 20, 2002Publication date: October 31, 2002Inventors: Mary Jane Meegan, Rosario Bridget Hughes, Daniela Maria Zisterer, David George Lloyd
-
Patent number: 6465457Abstract: Fungicidal compounds of formula (I): wherein W is CH3O.Type: GrantFiled: August 18, 1994Date of Patent: October 15, 2002Assignee: Zeneca LimitedInventors: Ian Richard Matthews, Christopher Richard Ayles Godfrey, John Martin Clough
-
Patent number: 6465458Abstract: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The methods comprise administering the optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.Type: GrantFiled: June 22, 2000Date of Patent: October 15, 2002Assignee: Pharmacia & UpJohn CompanyInventors: Erik H. F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor, Lars Birgerson, Pasquale Cetera
-
Patent number: 6458781Abstract: The present invention provides compounds that block calcium channels and have the Formula I: The present invention also provides pharmaceutical compositions containing the compounds of Formula I and methods of using them to treat stroke, cerebral ischemia, head trauma, and epilepsy.Type: GrantFiled: October 25, 1999Date of Patent: October 1, 2002Inventors: David Thomas Connor, Lain-Yen Hu, Thomas Charles Malone, Michael Francis Rafferty, Bruce David Roth, Todd Robert Ryder, Anthony Denver Sercel, Yuntao Song
-
Patent number: 6451817Abstract: This invention relates to the fields of pharmaceutical and organic chemistry and provides novel 1-benzyl-naphthyls which are &agr;-substituted with ether, thioether, amino, hydrazino, cyano or halo that are useful for the treatment of the various medical indications associated with post-menopausal syndrome, as well as estrogen dependent diseases including cancer of the breast, uterus and cervix. The present invention further relates to intermediate compounds and processes useful for preparing the pharmaceutically active compounds of the present invention, and pharmaceutical compositions.Type: GrantFiled: September 29, 1995Date of Patent: September 17, 2002Assignee: Eli Lilly and CompanyInventor: Brian S. Muehl
-
Patent number: 6441038Abstract: A method of treatment of disorders of neurological origin and drug formulations for use in the method are disclosed. These conditions comprise fatigue and associated syndromes of pain, weakness and depressed mood which are associated with chronic fatigue syndrome, brain injury and stroke, stress, fibromyalgia, and irritable bowel syndrome. The treatment comprises administering to a patient in need thereof a selective inhibitor of noradrenaline reuptake combined with either phenylalanine or tyrosine in the same dosage form or the same pack.# The noradrenergic drug may be selected from lofepramine, desipramine or reboxetine. The selective inhibitor may be a combined inhibitor of both noradrenaline and serotonin reuptake such as venlafaxine, duloxetine or milnacipran, or an inhibitor of both noradrenaline and dopamine reuptake such as bupropion.Type: GrantFiled: October 12, 2000Date of Patent: August 27, 2002Assignee: Laxdale LimitedInventors: Cari Loder, David F. Horrobin
-
Patent number: 6413961Abstract: A method and solution for perioperatively inhibiting a variety of pain, inflammation, spasm and restenosis processes resulting from cardiovascular or general surgical, therapeutic and diagnostic procedures. The solution preferably includes multiple pain and inflammation inhibitory agents, including at least one local anesthetic agent, and spasm inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. Specific preferred embodiments of the solution of the present invention for use in cardiovascular and general vascular procedures also include anti-restenosis agents.Type: GrantFiled: September 1, 1999Date of Patent: July 2, 2002Assignee: Omeros Medical Systems, Inc.Inventors: Gregory A. Demopulos, Pamela Anne Pierce, Jeffrey M. Herz
-
Patent number: 6391892Abstract: The present invention provides a compound of formula I wherein R1 is H, OH, halo, OCO(C1-C6 alkyl), OCO(aryl), OSO2(C4-C6 alkyl), OCOO(C1-C6 alkyl), OCOO(aryl), OCONH(C1-C6 alkyl), or OCON(C1-C6 alkyl)2; R2 is aryl, C1-C6 alkyl, C3-C6 cycloalkyl, or 4-cyclohexanol; R3 is O(CH2)2 or O(CH2)3; R4 and R5 are optionally CO(CH2)2CH3, CO(CH2)3CH3, C1-C6 alkyl, or R4 and R5 combine to form, with the nitrogen to which they are attached, piperidine, morpholine, pyrrolidine, 3-methylpyrrolidine, 3,3-dimethylpyrrolidine, 3,4-dimethylpyrrolidine, azepine, or pipecoline; and pharmaceutically acceptable salts thereof. The invention further provides pharmaceutical compositions containing compounds of formula I and methods of use for the compounds of formula I.Type: GrantFiled: March 10, 1995Date of Patent: May 21, 2002Assignee: Eli Lilly and CompanyInventors: Henry U. Bryant, Jeffrey A. Dodge
-
Patent number: 6391876Abstract: This invention relates to the use of reboxetine in the treatment of Obsessive Compulsive Disorders and Panic Disorders.Type: GrantFiled: October 19, 2000Date of Patent: May 21, 2002Assignee: Pharmacia and Upjohn CompanyInventors: Adriana Dubini, John Michael McCall, Duncan Paul Taylor, Philip F. Von Voigtlander, Erik Ho Fong Wong
-
Patent number: 6384053Abstract: This invention relates to the fields of pharmaceutical and organic chemistry and provides novel 1-benzyl-naphthyls which are &agr;-substituted with ether, thioether amino, cyano or halo that are useful for the treatment of the various medical indications associated with post-menopausal syndrome, as well as estrogen dependent diseases including cancer of the breast, uterus and cervix. The present invention further relates to intermediate compounds and processes useful for preparing the pharmaceutically active compounds of the present invention, and pharmaceutical compositions.Type: GrantFiled: March 10, 1995Date of Patent: May 7, 2002Assignee: Eli Lilly and CompanyInventor: Brian S. Muehl
-
Patent number: 6365131Abstract: Pharmaceutical dental gel preparation comprising of metronidazole benzoate, chlorhexidine gluconate, and local anesthetic as the active ingredient; glycol as the solvent medium; a carboxyvinyl polymer, cross-linked polymer of acrylic acid copolymerized with polyalkylsucrose as a gelling agent.Type: GrantFiled: January 10, 2000Date of Patent: April 2, 2002Assignee: J. B. Chemicals & Pharmaceuticals Ltd.Inventors: Madhukant Mansukhlal Doshi, Milind Dattatraya Joshi, Bharat Pravinchandra Mehta
-
Patent number: 6352986Abstract: This patent application describes the treatment of Addictive Disorders, Psychoactive Substance Use Disorders, Intoxication disorders, Inhalation disorders, Alcohol addiction, Tobacco Addiction and or Nicotine Addiction; and Attention Deficit Hyperactivity Disorder (ADHD); comprising administering a therapeutically effective, nontoxic dose of Reboxetine and derivatives and or pharmaceutically acceptable salts thereof to a patient.Type: GrantFiled: May 5, 2000Date of Patent: March 5, 2002Assignee: Pharmacia & Upjohn CompanyInventors: Fred Hassan, John Michael McCall, Duncan Paul Taylor, Philip F. Von Voigtlander, Erik Ho Fong Wong
-
Publication number: 20020016325Abstract: This patent application describes a new combination treatment of selective, noradrenaline-reuptake inhibitors (NARI) and specifically, reboxetine, and pindolol to provide rapid relief to patients suffering from depression, general anxiety, attention deficit hyperactivity disorder (ADHD), anxiety disorders such as obsessive compulsive disorders (OCD), panic disorders (PD), social phobia (SD) and the like.Type: ApplicationFiled: September 7, 2001Publication date: February 7, 2002Inventor: Duncan Paul Taylor
-
Patent number: 6335338Abstract: Novel calcilytic compounds are provided.Type: GrantFiled: February 7, 2001Date of Patent: January 1, 2002Assignee: SmithKline Beecham CorporationInventors: Pradip Bhatnagar, Maria Amparo Lago
-
Patent number: 6288261Abstract: Compounds having the formula and pharmaceutically acceptable salts and prodrugs thereof are matrix metalloproteinase inhibitors. Also disclosed are matrix metalloproteinase-inhibiting compositions and methods of inhibiting matrix metalloproteinase in a mammal.Type: GrantFiled: December 14, 1999Date of Patent: September 11, 2001Assignee: Abbott LaboratoriesInventors: David J. Augeri, David A. Betebenner, Richard Craig, Steven K. Davidsen, Stephen W. Fesik, Jamie R. Giesler-Stacey, Yan Guo, Philip J. Hajduk, Michael R. Michaelides, David G. Nettesheim
-
Patent number: 6284799Abstract: The present invention is concerned with the identification of compounds which increase the therapeutic index of chemotherapy drugs and which stimulate the growth of cancers, their use in the treatment of cancer and with certain novel compounds useful in such treatment.Type: GrantFiled: December 26, 1996Date of Patent: September 4, 2001Assignee: University of ManitobaInventor: Lorne J. Brandes
-
Patent number: 6184222Abstract: Norepinephrine reuptake inhibitors are used to treat conduct disorder.Type: GrantFiled: September 17, 1998Date of Patent: February 6, 2001Assignee: Eli Lilly and CompanyInventor: John Harrison Heiligenstein
-
Patent number: 6177067Abstract: Disclosed is a hair revitalizing tonic composition containing a dimethylpropanediol derivative of the formula: wherein R1 and R2 are each independently a C1-30 hydrocarbon group which may be substituted, or a five- or six-membered heterocyclic group which contains 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen atoms and which may be substituted, R3 is hydrogen atom, an alkyl group which may be substituted, an acyl group, an alkoxycarbonyl group, a phenoxycarbonyl group, or a carbamoyl group which may be substituted, and a and b are each 0 or 1, as well as a method for effecting hair growth promotion, hair growth stimulation, or hair loss prevention in mammals by using such a hair revitalizing tonic composition. Also disclosed is the use of a compound of formula (I) in the preparation of a hair revitalizing tonic composition. Thus, this invention can provide an excellent means of hair revitalization or hair loss prevention in mammals.Type: GrantFiled: October 13, 1998Date of Patent: January 23, 2001Assignees: Shiseido Company, Ltd., Takeda Chemical Industries, Ltd.Inventors: Tsunao Magara, Yoshiharu Tsuji, Masahiro Tajima, Koji Kobayashi, Hirotada Fukunishi, Masazumi Watanabe
-
Patent number: 6177427Abstract: Compositions of non-steroidal glucocorticoid antagonists for treating glaucoma or ocular hypertension and methods for their use are disclosed.Type: GrantFiled: July 1, 1999Date of Patent: January 23, 2001Assignee: Alcon Laboratories, Inc.Inventors: Abbot F. Clark, Raymond E. Conrow